Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Only one claim about treatment duration is provided, and it is marked as not supported due to mismatch with label specificity. Several other claims in the user-provided set are not evaluated here because the prompt includes a prior evaluation for a single extracted claim only; therefore overall alignment cannot be considered good.
Category Scores
Accurate Statements
Claim about use for complicated skin/skin structure infections and complicated intra-abdominal infections, and community-acquired bacterial pneumonia, for specified durations 5–14 days and 7–14 days respectively.
Supported in principle by FDA label section 2.1 (Recommended Adult Dosage) which provides recommended duration ranges by indication.
Unsupported Statements
The prior evaluation decision that the duration claim is 'not_supported' on the basis of possible mismatch with label specificity and risk of unsafe overextension.
The FDA label text provided in 2.1 explicitly states 5–14 days for complicated skin and skin structure infections and for complicated intra-abdominal infections, and 7–14 days for community-acquired bacterial pneumonia, with duration guided by severity/site and clinical/bacteriological progress. The cited label support directly matches the duration ranges stated in the claim.
Contradictions
Important Omissions
Does not reconcile the stated not-supported verdict with the exact duration ranges present in label section 2.1 (which appears to match the claim).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The evaluation concludes 'not_supported' despite apparent exact alignment of the duration ranges with label section 2.1; this mismatch could lead to incorrect downstream assessment of labeled dosing/duration accuracy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
The analysis marked the duration claim as 'not_supported' even though the provided label section 2.1 explicitly states the same duration ranges by indication.
Suggested Improvement
Re-check claim vs. label 2.1 wording: if duration ranges match exactly as stated (5–14 days for cSSSI/IAI and 7–14 days for CABP), mark as supported, and only flag issues if the claim deviates from the label (e.g., omitting the 'guided by severity/site and clinical and bacteriological progress' language).